AIR files PMTA for Crown Switch rechargeable pod vape platform
Dubai-based AIR Global filed a PMTA with the FDA for Crown Switch, a rechargeable pod platform built on Greentank's chip-based heating technology. The FDA must first decide whether to accept the filing for scientific review.
Key points
- AIR Global submitted a PMTA to the FDA for Crown Switch, a rechargeable pod vape platform, on 5 November 2026.
- The FDA must first decide whether to accept and file the application for scientific review, and may request more information or conduct inspections.
- AIR invested $20 million in Greentank in July 2026 and holds a warrant to increase its ownership stake by 20% over 24 months.
- Crown Switch uses Greentank's chip-based Quantum Vape aerosolisation system rather than coil-and-wick or ceramic heating.
- No FDA marketing authorisation for Crown Switch is stated in the filing announcement.
AIR Global has submitted a premarket tobacco product application to the US Food and Drug Administration for Crown Switch, a rechargeable pod-based vaping platform, the Dubai company announced on 5 November 2026. The filing starts a review the company does not control.
The FDA will first decide whether to accept and file the application for scientific review, according to the company’s release. During review the agency may request more information or conduct inspections. AIR’s own forward-looking statements list both the timing and the outcome of that review, including whether the FDA authorises marketing, as open.
What AIR says the filing contains
The application covers toxicology and aerosol chemistry, including how the heating system shapes the aerosol, together with clinical studies on pharmacokinetics and abuse liability and supporting non-clinical work. AIR also lists adult consumer perception, intention and switching research, individual- and population-level health impact assessments, and design, composition, manufacturing and quality-control data.
The package also addresses measures to limit youth access and use, and environmental considerations. AIR says its consumer research found strong interest in Crown Switch among current adult smokers, including stated intention to use it and likelihood of switching from combustible cigarettes. Those are the company’s findings as submitted, not an FDA conclusion.
Greentank supplies the heating system and holds a 20% warrant option
Crown Switch runs on Greentank’s Quantum Vape technology, a chip-based aerosolisation system that the company presents as different from conventional coil-and-wick and ceramic heating. AIR invested $20 million in Greentank in July 2026 by buying preferred shares, at a pre-money valuation of about $170 million, and holds a warrant to lift its stake by a further 20% over 24 months.
The product also carries a pod closure intended to reduce leakage and block refilling, child-resistant packaging, and a battery the company says was tested against recognised safety standards. AIR describes the device as rechargeable and pod-based.
Who the filing affects
US retailers and distributors cannot treat the submission as permission to sell Crown Switch. A PMTA is an application; marketing requires an FDA authorisation, and the agency has not granted one here. Distributors evaluating the brand should track the acceptance decision rather than the announcement.
The filing also matters to AIR’s investors, since the company is listed on Nasdaq under the ticker AIIR and the release carries forward-looking statements on the review, on US commercialisation timing and on its Greentank stake. AIR reports a presence in more than 90 markets, with brands including Al Fakher, NameLess and Al Aseel alongside Crown Switch in its portfolio.
Dates in the Crown Switch filing
| Step | Date or period | Status |
|---|---|---|
| AIR’s $20 million Greentank investment | July 2026 | Completed, per AIR |
| Warrant to add 20% ownership | 24 months from July 2026 | Option held by AIR |
| PMTA submitted to FDA | 5 November 2026 | Submitted |
| FDA acceptance and filing decision | Not stated | Pending |
Two of AIR’s own documents describe the Greentank deal differently in one respect: the release gives the investment figure and the warrant terms, while a separate company description covers the broader portfolio and intellectual property partnerships such as Crown Bar. Neither states an FDA decision date.
What comes next
The next public step is the FDA’s acceptance and filing decision on the Crown Switch application. Until that decision and any later authorisation, the product has no US marketing permission attached to this filing.
Questions readers ask
Can US retailers sell Crown Switch now?
No. AIR has submitted a PMTA, but the FDA has not authorised marketing. The agency must first decide whether to accept and file the application for scientific review, and may request more information or conduct inspections.
What heating technology does Crown Switch use?
Crown Switch runs on Greentank's Quantum Vape system, which AIR describes as chip-based aerosolisation that differs from conventional coil-and-wick and ceramic heating.
18+ only. This site is for adult readers and provides news and information only. It is not medical, legal or purchase advice. Nicotine is addictive. Always check the official text of any regulation in your market. Health Information
